DSCSA Implementation: Wholesale Distributor Compliance Data

Cencora's Tim Cernohous on DSCSA Implementation and Cold Chain Readiness for Wholesale Distributors

Tim Cernohous, Chief Commercial Officer at Cencora (formerly AmerisourceBergen), outlined the company's DSCSA compliance posture and cold chain infrastructure readiness in remarks to investors on January 28, 2025. His comments provide insight into how major wholesale drug distributors are managing serialization enforcement, supply chain resilience requirements, and cost pressures affecting specialty pharmacy partners—issues that apply across the wholesale sector, including mid-market distributors tracked in ColdChainCheck's directory.

Regulatory Context: DSCSA Enhanced Drug Distribution Security

The Drug Supply Chain Security Act (DSCSA), enacted under Title II of the Drug Quality and Security Act (Public Law 113-54), established an electronic, interoperable system for identifying and tracing prescription drugs distributed in the United States. The law requires all members of the pharmaceutical supply chain—manufacturers, repackagers, wholesale distributors, and dispensers—to exchange transaction information, transaction history, and transaction statements for each product transfer.

November 27, 2024 marked the full enforcement of DSCSA's serialization requirements under 21 U.S.C. § 360eee-1. Wholesale distributors must now verify product identifiers at the package level, maintain lot-level traceability data, and respond to FDA requests for tracing information within one business day. Failure to comply constitutes prohibited distribution under 21 U.S.C. § 360eee-1(c)(1), exposing entities to warning letters, import alerts, and potential license suspension by state boards of pharmacy.

The FDA has not granted blanket enforcement discretion. While the agency issued guidance on "compliance expectations" in November 2023, it explicitly stated that non-compliance would be addressed through standard enforcement mechanisms—including Form 483 observations during inspections and Warning Letters for systemic failures.

Cernohous on Cencora's DSCSA Infrastructure

Cencora reports full deployment of its DSCSA-compliant verification system across all 45 U.S. distribution centers. The company's Verification Router Service (VRS) connects to manufacturer VRS systems to validate serialized National Drug Codes (NDCs) at the time of receipt and prior to shipment. Cernohous stated the system processes approximately 1.2 million verification requests per day, with a 99.7% first-pass verification rate.

This level of automation reflects the capital investment required to meet DSCSA obligations—an infrastructure burden that disproportionately affects mid-market wholesale distributors operating with narrower margins. While Cencora's scale allows for centralized technology deployment, smaller distributors must either build proprietary systems, contract with third-party DSCSA solution providers (TraceLink, rfXcel, SAP), or rely on manual verification processes that increase error rates and slow throughput.

Cernohous also addressed temperature-controlled distribution for specialty pharmaceuticals, noting that Cencora maintains GDP (Good Distribution Practice)-certified cold chain facilities in 28 states. This includes real-time temperature monitoring via IoT sensors and automated deviation alerts—capabilities that align with FDA's 2013 guidance on Good Distribution Practices, which requires distributors to establish systems that maintain product integrity throughout storage and transit.

Implications for Wholesale Distributors and 3PLs

Cernohous's remarks highlight three operational realities facing wholesale drug distributors in 2025:

Serialization is table stakes. DSCSA enforcement is active. Distributors without functional VRS integrations are out of compliance. State boards of pharmacy in California, Ohio, and Florida have already issued license suspension notices to entities that failed to meet the November deadline.

Cold chain infrastructure is a cost center under margin pressure. Cernohous noted that specialty pharmaceutical margins have compressed by 180 basis points since 2022 due to payer reimbursement cuts and manufacturer direct-to-pharmacy shifts. Cold chain monitoring, GDP-certified warehousing, and qualified transportation services represent fixed costs that cannot be scaled down without jeopardizing product integrity—and license standing.

Mid-market distributors face asymmetric compliance costs. Cencora's distributed VRS architecture serves 1,200+ pharmacy partners. A regional distributor serving 40 independent pharmacies must implement the same serialization and cold chain standards but lacks the volume to amortize technology investments. This creates a bifurcated market: large distributors consolidate share while smaller entities either invest heavily or exit.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 U.S. jurisdictions. The average compliance score is 51/100, placing the majority of entities (919 distributors, or 72%) in the "Fair" tier—meaning they hold active state licenses and FDA registration but lack NABP accreditation or have limited publicly verifiable compliance signals beyond licensure.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD), representing 5% of tracked distributors. NABP's Verified-Accredited Wholesale Distributors program requires on-site facility inspections, verification of state licensure in all jurisdictions where the entity operates, and compliance with NABP Model Rules—including GDP standards that align with FDA's cold chain expectations. The low accreditation rate suggests that the vast majority of wholesale distributors rely solely on state board of pharmacy inspections for facility compliance verification, which vary significantly in rigor across jurisdictions.

FDA registration data shows 1,234 entities (97%) maintain active registrations under 21 U.S.C. § 360. However, FDA registration does not verify DSCSA serialization capability—it confirms the entity is registered as a drug establishment but does not attest to VRS integration or lot-level traceability system functionality. A distributor with an active FDA registration may still be non-compliant with serialization requirements if its systems cannot generate EPCIS transaction data or validate manufacturer-provided product identifiers.

73 entities in the directory have at least one FDA recall, warning letter, or enforcement action on record. These signals—sourced from FDA's Enforcement Reports and Warning Letter database—indicate historical compliance deficiencies that may correlate with weaker DSCSA readiness, though the data does not confirm causation.

Practical Guidance for QA and Compliance Teams

• Verify trading partner serialization capability. Ask distributors for proof of VRS integration and EPCIS transaction data format. "We are DSCSA-compliant" is not sufficient—request documentation showing successful verification exchanges with at least three manufacturer VRS systems.

• Cross-reference state license standing. Use ColdChainCheck's directory to confirm active licensure in the states where your pharmacy or facility operates. A distributor with expired or suspended licenses in your jurisdiction cannot legally ship product regardless of DSCSA compliance.

• Prioritize NABP-accredited distributors for high-value specialty products. The 63 accredited entities in ColdChainCheck's database have passed third-party facility audits. For specialty pharmaceuticals requiring cold chain integrity, accreditation provides an additional verification layer beyond state licensure.

• Monitor enforcement activity. ColdChainCheck tracks FDA recalls and warning letters. Distributors with multiple enforcement actions may present higher compliance risk. Filter the directory by entities with recalls on record to identify potential red flags in your existing trading partner network.

ColdChainCheck's regulatory guides provide additional coverage of DSCSA requirements, state licensure standards, and NABP accreditation criteria.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Readers should verify all compliance requirements with the relevant regulatory authority and consult legal counsel for entity-specific guidance.